CN107158041A - A kind of probiotic composition for being used to treat gynaecological imflammation - Google Patents

A kind of probiotic composition for being used to treat gynaecological imflammation Download PDF

Info

Publication number
CN107158041A
CN107158041A CN201710445975.9A CN201710445975A CN107158041A CN 107158041 A CN107158041 A CN 107158041A CN 201710445975 A CN201710445975 A CN 201710445975A CN 107158041 A CN107158041 A CN 107158041A
Authority
CN
China
Prior art keywords
composition
parts
gynaecological imflammation
cfu
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710445975.9A
Other languages
Chinese (zh)
Inventor
李珮铷
贾长生
边高瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Ty Health Biotechnology Co ltd
Original Assignee
Zhejiang Ty Health Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Ty Health Biotechnology Co ltd filed Critical Zhejiang Ty Health Biotechnology Co ltd
Priority to CN201710445975.9A priority Critical patent/CN107158041A/en
Publication of CN107158041A publication Critical patent/CN107158041A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A kind of composition for being used to treat gynaecological imflammation that the present invention is provided, includes the component of following parts by weight：30 40 parts of resistant dextrin, the powder of inulin 40 60,28 parts of stachyose, Lactobacillus rhamnosus TR08 (0.1 10) × 1012CFU, lactobacillus reuteri TR02 (0.1 10) × 1012CFU.Said composition preparation technology is simple, raw material sources are extensive, with low cost, easy to use, and treatment gynaecological imflammation effect is good.

Description

A kind of probiotic composition for being used to treat gynaecological imflammation
Technical field
The invention belongs to biological technical field, a kind of probiotic composition for being used to treat gynaecological imflammation is especially related to.
Background technology
Gynaecological imflammation refers to the caused disease of female genital system infection, and gynaecological imflammation is individual common in daily life Disease is also intractable diseases, and sick hair rate is high especially in married woman, common symptom have irregular menstruation, dysmenorrhoea, adnexitis, Pelvic infecton, cervicitis, endometritis, vaginal discharge have peculiar smell etc., and what is had even causes infertile.Gynaecological imflammation Illness rate is high, and high recurrence rate drastically influence the physical and mental health of women.
A variety of Lower Female Genital Tract diseases are due to that the imbalance of microecology in vaginas system balancing is caused, such as bacterial vaginitis, Colpomycosis, trichomonas vaginitis etc..The measure for the treatment of vagina infection at present is mainly with antibiotic, metronidazole, female Hormone and it is acidified preparation etc. of vagina to kill the pathogenic microorganism of intravaginal.But, above-mentioned therapy to a certain extent can Suppress normal flora, cause the excessive multiplication of pathogenic bacteria or conditioned pathogen, so as to cause repeated infection or multiple infection, increase Plus the difficulty and cost for the treatment of.Medicine use time is long will to produce drug resistance, there is certain side effect to hepatic and renal function, Larger is endangered to patient.And it is long using Chinese medicine or Chinese patent drugs for treatment time, therapeutic effect is not satisfactory.At present, genital tract is adjusted Flora, if using probiotics, it is oral of less types generally by interior use suppository, in-convenience in use.
The content of the invention
Technical problem：In order to solve the defect of prior art, the invention provides a kind of benefit for being used to treat gynaecological imflammation Raw bacteria composition.
Technical scheme：A kind of composition for being used to treat gynaecological imflammation that the present invention is provided, includes the group of following parts by weight Part：30-40 parts of resistant dextrin, inulin 40-60 powder, 2-8 parts of stachyose, Lactobacillus rhamnosus TR08 (0.1-10) × 1012CFU, Lactobacillus reuteri TR02 (0.1-10) × 1012CFU。
As an improvement, including the component of following parts by weight：35 parts of resistant dextrin, the powder of inulin 50,5 parts of stachyose, rhamnose Lactobacillus TR08 1012CFU, lactobacillus reuteri TR02 1012CFU。
Present invention also offers the above-mentioned preparation method for being used to treat the composition of gynaecological imflammation, resistance paste is weighed respectively Essence, inulin, stachyose, are mixed；Lactobacillus rhamnosus TR08, lactobacillus reuteri TR02 are added, mixes, produces.
Present invention also offers application of the above-mentioned composition in treatment gynaecological imflammation medicine is prepared.
Present invention also offers above-mentioned composition and antibiotic in answering in treatment gynaecological imflammation combination medicine is prepared With.
The application, the antibiotic includes CLA, Amoxicillin, azithromycin, penicillin, cefuroxime, four One or more in ring element, metronidazole.
Beneficial effect：Composition preparation technology that the present invention is provided is simple, raw material sources are extensive, with low cost, user Just, treatment gynaecological imflammation effect is good.
Brief description of the drawings
Fig. 1 is lactobacillus reuteri (Lactobacillus reuteri) TR02 bacterium colony figure.
Fig. 2 is lactobacillus reuteri (Lactobacillus reuteri) TR02 bacterium colony enlarged drawing.
Fig. 3 is Lactobacillus rhamnosus (Lactobacillus rhamnosus) TR08 bacterium colony figure.
Fig. 4 is Lactobacillus rhamnosus (Lactobacillus rhamnosus) TR08 bacterium colony enlarged drawing.
Fig. 5 is the diversity indices figure of embodiment.
Fig. 6 is lgG, IgA, IgM concentration map in the probiotic group serum sample of embodiment.
Fig. 7 is the Double-blind randomized clinical trial with metronidazole (metronidazole) therapeutic alliance bacterial vaginitis group Result figure.
Embodiment
Stachyose is purchased from Shandong Xi Wang groups
Inulin is purchased from the Long Chuan gardens biotech inc of Shandong hundred
Resistant dextrin is purchased from the Long Chuan gardens biotech inc of Shandong hundred
Lactobacillus reuteri (Lactobacillus reuteri) TR02, its Classification And Nomenclature is lactobacillus reuteri (Lactobacillus reuteri) TR02, in China typical culture collection center (abbreviation CCTCC) preservation, depositary institution Address：Wuhan City, Hubei Province Wuchang District Wuhan University, postcode is 430072, and its deposit number is：CCTCC No.2016546, preservation date is on October 10th, 2016.
The separation of bacterial strain
1st, strain and culture medium and condition of culture
(1) bacterium source
From the healthy soldier's excrement in certain the Chinese military region.
(2) culture medium
Plating medium：1000mL distilled water, peptone 10g, glucose 20g, dusty yeast 9g, sodium acetate 5g, phosphoric acid hydrogen Dipotassium 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g, tween 1ml, agar powder 15-20g, pH5.5-6.5。
2nd, the separation and identification of bacterial strain
(1) separation of bacterial strain
Proper amount of fresh excrement is taken to be placed in the sterile examination for being loaded with aseptic culture medium in glove box after advance sterilized processing Guan Zhong, fully shaking, which is vortexed, to be mixed；
The excrement solution mixed is vortexed as stoste using above-mentioned fully shaking, ten times of gradient dilutions is done to suitable gradient, takes 100 μ l are spread evenly across on MRS+0.05% cysteine solid plate culture mediums, are then taken out and are placed in anaerobic jar, 37 DEG C of anaerobism Overnight incubation.
Bacterium colony with form different sizes on next day visible flat board, it is special with reference to lactobacillus reuteri colonies typical form Levy, some representational bacterium colonies of picking make two generations line purification process, flat board anaerobism activates 1 day, obtains culture, then do bacterium Strain identification.
(2) identification of bacterial strain
Gram's staining Morphological Identification：
A, smear：Take sterilized slide on experimental bench, marked on slide with marking pen, be easy to observation, with Slide is inverted afterwards, then drawing 10 μ l sterile salines with pipettor is uniformly coated at mark, is then chosen with liquid-transfering gun Pure culture is taken uniformly to be dissolved in physiological saline, coated face is unsuitable excessive.
B, drying：By sample upwardly, the both sides of hand-held slide one end, carefully eminence adds slightly on alcolhol burner Heat, makes moisture evaporation, but is sure not long against flame or heat time, bakes withered to prevent sample and deforms.
C, fixation：Fixed usually to utilize high temperature, one end of hand-held slide, sample is upward, at alcolhol burner flame as early as possible Back and forth through 2-3 times, plant within about 2-3 second altogether, and skin is touched with the heating of the slide back side frequently, can not help boiling hot be advisable and (do not surpass Cross 60 DEG C), place after cold, dyed.
D, just dye：Ammonium oxalate crystal violet 1-2 drops are added dropwise on smear film, dyeing liquor is covered smear, about 1min is dyed.
E, washing：Tilting slide, is rinsed under water tap with shallow bid current, until the water under washing is in colourless Only.
F, mordant dyeing：About 300ul iodine solutions are drawn with 100-1000ul liquid-transfering guns to drop on smear film, make dyeing liquor covering painting Piece, dyes about 1min.
G, washing：Tilting slide, is rinsed under water tap with shallow bid current, until the water under washing is in colourless Only.
H, decolouring：Tilting slide, is added dropwise 95% ethanol decolorization, untill the ethanol of outflow does not show purple, about takes 20-30S, is washed immediately.
I, redye：Husky of common dye dye liquor 1-2 drops are added dropwise on smear film, dyeing liquor is covered smear, about 1min is dyed.
J, washing：Tilting slide, is rinsed under water tap with shallow bid current, until the water under washing is in colourless Only.
K, drying, observation：Water droplet is sopped up with blotting paper, treats that sample slice is done under rearmounted microscope, low power sem observation is used, found Immersion oil is dripped after purpose thing on slide, the form and color of bacterium are observed with oil mirror, purple is gram-positive bacteria, red Color is Gram-negative bacteria.
As a result show：The bacterial strain is gram-positive bacteria.
The measure of 16S rRNA sequences：
The primer that the PCR amplifications of 16S rRNA genes are used is the primer of general bacterium --- 8F (5 '- CACGGATCCAGAGTTTGAT (C/T) (A/C) TGGCTCAG-3 ') and 1510R (5 '-GTGAAGCTTAGGG (C/T) TACCTTGTTACGACTT-3 ') the qualified third party laboratory progress sanger sequencings of product commission.Using BLAST algorithm Sequence and 16S rRNA genes are compared in GenBank databases, adjacent tree is set up using the programs of MEGA 4.0.
BLAST analyses show that TR02 bacterium are sufficiently close to lactobacillus reuteri (99% relationship (as shown in SEQ ID No.1) Property).
Lactobacillus rhamnosus (L.rhamnosus) TR08, its Classification And Nomenclature is Shu Litangshi lactobacillus (Lactobacillus rhamnosus) TR08, in China typical culture collection center (abbreviation CCTCC) preservation, preservation list Bit address：Wuhan City, Hubei Province Wuchang District Wuhan University, postcode is 430072, and its deposit number is：CCTCC NO.M 2016548, preservation date is on October 10th, 2016.
The separation of bacterial strain
1st, strain and culture medium and condition of culture
(1) bacterium source
From the healthy soldier's excrement in certain the Chinese military region
(2) culture medium
Plating medium：1000mL distilled water, peptone 10g, glucose 20g, dusty yeast 9g, sodium acetate 5g, phosphoric acid hydrogen Dipotassium 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g, tween 1ml, agar powder 15-20g, pH5.5-6.5。
2nd, the separation and identification of bacterial strain
(1) separation of bacterial strain
Proper amount of fresh excrement is taken to be placed in the sterile examination for being loaded with aseptic culture medium in glove box after advance sterilized processing Guan Zhong, fully shaking, which is vortexed, to be mixed；
The excrement solution mixed is vortexed as stoste using above-mentioned fully shaking, ten times of gradient dilutions is done to suitable gradient, takes 100 μ l are spread evenly across on MRS+0.05% cysteine solid plate culture mediums, are then taken out and are placed in anaerobic jar, 37 DEG C of anaerobism Overnight incubation.
Bacterium colony with form different sizes on next day visible flat board, with reference to lactobacillus colonies typical morphological feature, picking Some representational bacterium colonies make two generations line purification process, and flat board anaerobism activates 1 day, obtains culture, then do bacterial strain identification.
(2) identification of bacterial strain
Gram's staining Morphological Identification：
A, smear：Take sterilized slide on experimental bench, marked on slide with marking pen, be easy to observation, with Slide is inverted afterwards, then drawing 10 μ l sterile salines with pipettor is uniformly coated at mark, is then chosen with liquid-transfering gun Pure culture is taken uniformly to be dissolved in physiological saline, coated face is unsuitable excessive.
B, drying：By sample upwardly, the both sides of hand-held slide one end, carefully eminence adds slightly on alcolhol burner Heat, makes moisture evaporation, but is sure not long against flame or heat time, bakes withered to prevent sample and deforms.
C, fixation：Fixed usually to utilize high temperature, one end of hand-held slide, sample is upward, at alcolhol burner flame as early as possible Back and forth through 2-3 times, plant within about 2-3 second altogether, and skin is touched with the heating of the slide back side frequently, can not help boiling hot be advisable and (do not surpass Cross 60 DEG C), place after cold, dyed.
D, just dye：Ammonium oxalate crystal violet 1-2 drops are added dropwise on smear film, dyeing liquor is covered smear, about 1min is dyed.
E, washing：Tilting slide, is rinsed under water tap with shallow bid current, until the water under washing is in colourless Only.
F, mordant dyeing：About 300ul iodine solutions are drawn with 100-1000ul liquid-transfering guns to drop on smear film, make dyeing liquor covering painting Piece, dyes about 1min.
G, washing：Tilting slide, is rinsed under water tap with shallow bid current, until the water under washing is in colourless Only.
H, decolouring：Tilting slide, is added dropwise 95% ethanol decolorization, untill the ethanol of outflow does not show purple, about takes 20-30S, is washed immediately.
I, redye：Husky of common dye dye liquor 1-2 drops are added dropwise on smear film, dyeing liquor is covered smear, about 1min is dyed.
J, washing：Tilting slide, is rinsed under water tap with shallow bid current, until the water under washing is in colourless Only.
K, drying, observation：Water droplet is sopped up with blotting paper, treats that sample slice is done under rearmounted microscope, low power sem observation is used, found Immersion oil is dripped after purpose thing on slide, the form and color of bacterium are observed with oil mirror, purple is gram-positive bacteria, red Color is Gram-negative bacteria.
As a result show：The bacterial strain is gram-positive bacteria.
The measure of 16S rRNA sequences：
The primer that the PCR amplifications of 16S rRNA genes are used is the primer of general bacterium --- 8F (5 '- CACGGATCCAGAGTTTGAT (C/T) (A/C) TGGCTCAG-3 ') and 1510R (5 '-GTGAAGCTTAGGG (C/T) TACCTTGTTACGACTT-3 ') the qualified third party laboratory progress sanger sequencings of product commission.Using BLAST algorithm Sequence and 16S rRNA genes are compared in GenBank databases, adjacent tree is set up using the programs of MEGA 4.0.
BLAST analyses show that TR02 bacterium are sufficiently close to Lactobacillus rhamnosus (99% relationship (as shown in SEQ ID No.2) Property).
Embodiment 1
Composition for treating gynaecological imflammation, includes the component of following parts by weight：30 parts of resistant dextrin, the powder of inulin 60, 2 parts of stachyose, Lactobacillus rhamnosus TR08 0.1 × 1012CFU, lactobacillus reuteri TR02 10 × 1012CFU。
Embodiment 2
Composition for treating gynaecological imflammation, includes the component of following parts by weight：40 parts of resistant dextrin, the powder of inulin 40, 8 parts of stachyose, Lactobacillus rhamnosus TR08 10 × 1012CFU, lactobacillus reuteri TR02 0.1 × 1012CFU。
Embodiment 3
Composition for treating gynaecological imflammation, includes the component of following parts by weight：35 parts of resistant dextrin, the powder of inulin 50, 5 parts of stachyose, Lactobacillus rhamnosus TR08 1 × 1012CFU, lactobacillus reuteri TR02 1 × 1012CFU。
The nutritional ingredient of the composition of embodiment 1 to 3 is detected, 1 is shown in Table.
Table 1
The composition of embodiment 1 to 3 is used to treat gynaecological imflammation.
Experiment one：Treat bacterial vaginitis and colpomycosis.
Crowd to be tested is divided into some groups：
Healthy group (Healthy)：
BV groups (bacterial vaginitis group)：
Placebo 1 (Placebo)：Using placebo treatment 28 days；
Probiotic group 1 (Probiotic)：Using the composition treatment 28 days of the embodiment of the present invention 3；
VVC groups (colpomycosis group)：
Placebo 2 (Placebo)：Using placebo treatment 28 days；
Probiotic group 2 (Probiotic)：Using the composition treatment 28 days of the embodiment of the present invention 3.
As a result show：
(1) diversity indices of each group is tested, Fig. 5 is seen；
BV groups are substantially invalid using placebo treatment, and use the composition treatment diversity of embodiment 3 to substantially reduce, and treat Effect is fine；
VVC groups are effective using the composition of placebo and embodiment 3.
(3) lgG, IgA, IgM concentration (g/L) in test probiotic group serum sample, are shown in Fig. 6；
In individual probiotic oral 28 days, concentration is low than not eating for lgG, IgM concentration in serum, and IGA is not than eating Probiotics is higher.
Experiment two：Aid in antibiotic therapy colpomycosis.
Crowd to be tested is divided into some groups：
Antibiotic probiotic combination treatment group：Receive CLA (or Amoxicillin, azithromycin, penicillin, cephalo furan Pungent, tetracycline) treatment 10d；Receive the composition treatment 21d of embodiment 3 simultaneously；
Antibiotic placebo therapeutic alliance group：Receive CLA (or Amoxicillin, azithromycin, penicillin, cephalo furan Pungent, tetracycline) treatment 10d；Receive placebo treatment 21d simultaneously；
Take within 0th day, the 30th day vaginal swab Nugent to score, the results are shown in Table 2.
Table 2
As a result show：VMB Flora Disturbances caused by the composition of embodiment 3 can significantly improve antibiotic, prevention VVC/BV (P <0.05)。
Experiment three：Tried with the double-blind, randomized controlled clinical study of metronidazole (metronidazole) therapeutic alliance bacterial vaginitis group Test.
Bacterial vaginitis (BV) women is divided into two groups：
LACTO groups：49 people use the composition therapeutic alliance of metronidazole and embodiment 3；
Placebo groups：57 people use placebo and metronidazole therapeutic alliance.
With Nugent scorings and BV-blue test, the tracking that BV treats follow-up 30 days BV recurrence rates is assessed.
As a result, see Fig. 7, show：Metronidazole combines probiotics agents treatment, significantly reduces BV recurrence rates (p<0.001).
Experiment four：The composition of embodiment 1 to 3 is used to treat bacterial vaginitis
Control group 1：Effect of Oral Metronidazole piece, 3 times a day, is used in conjunction 10 days.
Control group 2：Oral control drug 2,3 times a day, is used in conjunction 10 days；Wherein, control drug 2 is to include following parts by weight Component composition：35 parts of resistant dextrin, the powder of inulin 50,5 parts of stachyose, Lactobacillus rhamnosus TR08 2 × 1012CFU；
Control group 3：Oral control drug 3,3 times a day, is used in conjunction 10 days；Wherein, control drug 3 is to include following parts by weight Component composition：35 parts of resistant dextrin, the powder of inulin 50,5 parts of stachyose, lactobacillus reuteri TR02 2 × 1012CFU；
Treatment group 1：The composition of the oral embodiment of the present invention 1,3 times a day, is used in conjunction 10 days.
Treatment group 2：The composition of the oral embodiment of the present invention 1,3 times a day, is used in conjunction 10 days.
Treatment group 3：The composition of the oral embodiment of the present invention 1,3 times a day, is used in conjunction 10 days.
Curative effect judging standard：Treatment target checks vaginal secretion at 2 weeks after treating 1 course for the treatment of and after next clean period Thing.
Recovery from illness：4 negative, clinical symptom disappearances in BV diagnostic criteria.
It is effective：Only 1 positive, clinical symptom disappearance in BV diagnostic criteria.
Effectively：Only 2 positives in BV diagnostic criteria, clinical symptoms are obviously improved.
It is invalid：3 positives in BV diagnostic criteria, clinical symptoms are without improvement.
Treatment results：It is shown in Table 3.
The total effectses of table 3 compare
Note：Treatment group's curative effect is better than control group.
Two groups of recurrence rates compare：
Table 4
Group Control group 1 Control group 2 Control group 3 Treatment group 1 Treatment group 2 Treatment group 3
Recurrence rate % 6/81 9/78 8/80 0/95 1/95 0/95
SEQUENCE LISTING
<110>Tian Yi health sciences research institute（Zhenjiang）Co., Ltd
<120>A kind of Lactobacillus rhamnosus and its application
<130> SC20161008002
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 1490
<212> DNA
<213> Lactobacillus reuteri
<220>
<221> misc_feature
<222> (1)..(1490)
<400> 1
gggtacgcgg cggtgtgcta tacatgcaag tcgtacgcac tggcccaact gattgatggt 60
gcttgcacct gattgacgat ggattaccag tgagtggcgg acgggtgagt aacacgtagg 120
taacctgccc cggagcgggg gataacattt ggaaacagat gctaataccg cataacaaca 180
aaagccacat ggcttttgtt tgaaagatgg ctttggctat cactctggga tggacctgcg 240
gtgcattagc tagttggtaa ggtaacggct taccaaggcg atgatgcata gccgagttga 300
gagactgatc ggccacaatg gaactgagac acggtccata ctcctacggg aggcagcagt 360
agggaatctt ccacaatggg cgcaagcctg atggagcaac accgcgtgag tgaagaaggg 420
tttcggctcg taaagctctg ttgttggaga agaacgtgcg tgagagtaac tgttcacgca 480
gtgacggtat ccaaccagaa agtcacggct aactacgtgc cagcagccgc ggtaatacgt 540
aggtggcaag cgttatccgg atttattggg cgtaaagcga gcgcaggcgg ttgcttaggt 600
ctgatgtgaa agccttcggc ttaaccgaag aagtgcatcg gaaaccgggc gacttgagtg 660
cagaagagga cagtggaact ccatgtgtag cggtggaatg cgtagatata tggaagaaca 720
ccagtggcga aggcggctgt ctggtctgca actgacgctg aggctcgaaa gcatgggtag 780
cgaacaggat tagataccct ggtagtccat gccgtaaacg atgagtgcta ggtgttggag 840
ggtttccgcc cttcagtgcc ggagctaacg cattaagcac tccgcctggg gagtacgacc 900
gcaaggttga aactcaaagg aattgacggg ggcccgcaca agcggtggag catgtggttt 960
aattcgaagc tacgcgaaga accttaccag gtcttgacat cttgcgctaa ccttagagat 1020
aaggcgttcc cttcggggac gcaatgacag gtggtgcatg gtcgtcgtca gctcgtgtcg 1080
tgagatgttg ggttaagtcc cgcaacgagc gcaacccttg ttactagttg ccagcattaa 1140
gttgggcact ctagtgagac tgccggtgac aaaccggagg aaggtgggga cgacgtcaga 1200
tcatcatgcc ccttatgacc tgggctacac acgtgctaca atggacggta caacgagtcg 1260
caagctcgcg agagtaagct aatctcttaa agccgttctc agttcggact gtaggctgca 1320
actcgcctac acgaagtcgg aatcgctagt aatcgcggat cagcatgccg cggtgaatac 1380
gttcccgggc cttgtacaca ccgcccgtca caccatggga gtttgtaacg cccaaagtcg 1440
gtggcctaac ctttatggag ggagccgcct aaggcggaca gagactgggt 1490
<210> 2
<211> 1474
<212> DNA
<213> Lactobacillus rhamnosus
<220>
<221> misc_feature
<222> (1)..(1474)
<400> 1
cgctggcggc gtgcctaata catgcaagtc gaacgagttc tgattattga aaggtgcttg 60
catcttgatt taattttgaa cgaatggcgg aagggtgaat aacccgtggg taacctggcc 120
ttaaatgggg gataaccttt ggaaaccgaa gctaataccg cataaatccc aaaaccgcat 180
ggttcttggc tgaaagatgg ggtaaactat cccttttgga tggacccccg gcgtattaac 240
ttgttggtga ggtaacggct ccaccaggga atgataccta acccaactga aaggttgatc 300
ggccaccttg ggactgagac ccggcccaaa ctcctaccgg agggagcaat agggaatctt 360
ccccaatgga cgccagtctg aaggaacaac cccccgtggg tgaaaaaggg tttccggtcc 420
taaaactctg ttgttggaaa aaaatggtcc gcaaaataac tggtggccgc gtggccgtat 480
ccaacccgaa agccacggct aactacctgc ccagcaccgc ggtaataccg aggtggcaag 540
cgttatccgg atttattggg cgtaaagcga gcgcaagcgg gttttttagt ctgatgggaa 600
agccctcggc ttaaccgaag aagtgcatcg gaaactggga aacttgaatg cagaagaaga 660
cagtggaact ccatgtgtag cggtgaaatg cctagatata tggaagaaca ccagtggcga 720
aagccgctgt ctggtctgta actgacgctg aagctccaaa gcctgggtag cgaacaggat 780
tagataccct gggagtccat gccgtaacga tgaatgctag tggtggaagg tttccgccct 840
tcaatgccga gcttacgcaa taagcaatcc gcctggggga atacgaccgg caggttgaaa 900
cttcaaagaa tttgaccggg gccgcacaag ccggtggagc attgtggttt aattcgaagc 960
acgcgaagaa cttaccaggt cttgacatct tttgatcact tgaagatcaa gtttcccttc 1020
gggcaaatga cagtggtgca tggttgtcgt cagctccgtg tcgtgagatg ttgggttaag 1080
tcccgcaacg agcgcaaccc ttatgactag ttgccagcat ttagttgggc actctagtaa 1140
gactgccggt gacaaaccgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg 1200
acctgggcta cacacgtgct acaatggatg gtacaacgag ttgcgagacc gcgaggtcaa 1260
gctaatctct taaagccatt ctcagttcgg actgtaggct gcaactcgcc tacacgaagt 1320
cggaatcgct agtaatcgcg gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac 1380
acaccgcccg tcacaccatg agagtttgta acacccgaag ccggtggcgt aaccctttta 1440
gggagcgagc cgtctaaggt ggacaaatga tact 1474

Claims (6)

1. a kind of composition for being used to treat gynaecological imflammation, it is characterised in that：Include the component of following parts by weight：Resistant dextrin 30-40 parts, inulin 40-60 powder, 2-8 parts of stachyose, Lactobacillus rhamnosus TR08 (0.1-10) × 1012CFU, lactobacillus reuteri TR02(0.1-10)×1012CFU。
2. a kind of composition for being used to treat gynaecological imflammation according to claim 1, it is characterised in that：Including following weight The component of part：35 parts of resistant dextrin, the powder of inulin 50,5 parts of stachyose, Lactobacillus rhamnosus TR08 1012CFU, lactobacillus reuteri TR02 1012CFU。
3. a kind of preparation method for being used to treat the composition of gynaecological imflammation described in claim 1, it is characterised in that：Claim respectively Resistant dextrin, inulin, stachyose are taken, is mixed；Lactobacillus rhamnosus TR08, lactobacillus reuteri TR02 are added, is mixed, i.e., .
4. application of the composition in treatment gynaecological imflammation medicine is prepared described in any one of claim 1 to 2.
5. the composition and antibiotic described in any one of claim 1 to 2 are in treatment gynaecological imflammation combination medicine is prepared Application.
6. application as claimed in claim 5, it is characterised in that：The antibiotic includes CLA, Amoxicillin, Zitromax One or more in element, penicillin, cefuroxime, tetracycline, metronidazole.
CN201710445975.9A 2017-06-14 2017-06-14 A kind of probiotic composition for being used to treat gynaecological imflammation Pending CN107158041A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710445975.9A CN107158041A (en) 2017-06-14 2017-06-14 A kind of probiotic composition for being used to treat gynaecological imflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710445975.9A CN107158041A (en) 2017-06-14 2017-06-14 A kind of probiotic composition for being used to treat gynaecological imflammation

Publications (1)

Publication Number Publication Date
CN107158041A true CN107158041A (en) 2017-09-15

Family

ID=59818448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710445975.9A Pending CN107158041A (en) 2017-06-14 2017-06-14 A kind of probiotic composition for being used to treat gynaecological imflammation

Country Status (1)

Country Link
CN (1) CN107158041A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106509612A (en) * 2016-10-28 2017-03-22 完美（中国）有限公司 Usage of fiber composition for preparing foods for improving polycystic ovary syndrome
CN106511976A (en) * 2016-10-25 2017-03-22 天益健康科学研究院（镇江）有限公司 Composition for relieving gynecologic inflammation and improving immunity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106511976A (en) * 2016-10-25 2017-03-22 天益健康科学研究院（镇江）有限公司 Composition for relieving gynecologic inflammation and improving immunity
CN106509612A (en) * 2016-10-28 2017-03-22 完美（中国）有限公司 Usage of fiber composition for preparing foods for improving polycystic ovary syndrome

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
SEIDNER D L ET AL: "An oral supplement enriched with fish oil，soluble fiber，and antioxidants for corticosteroid sparing in ulcerative colitis：A randomized，controlled trial", 《CLINIC GASTROENTEROL AND HEPATOL》 *
崔岸等: "《自然生物疗法：益生菌保健与使用指南》", 31 December 2006, 华南理工大学出版社 *
张振等: "《益生菌在儿科临床中的应用》", 31 January 2011, 湖北科学技术出版社 *
徐仰丽等: "抗性糊精的研究进展", 《河南工业大学学报(自然科学版)》 *
石立民等: "可溶性膳食纤维抗炎症研究进展", 《粮食与油脂》 *

Similar Documents

Publication Publication Date Title
CN104630083B (en) A kind of Lactobacillus crispatus and its application in feminine care products
JP7354274B2 (en) Complex lactobacillus composition and its use in female vaginal health
TWI652343B (en) Lactobacillus crimper (LACTOBACILLUS Crispatus) and application thereof
CN104560820B (en) VREF KQ2.6 and application
CN106509913A (en) Composition for regulating balance of intestinal flora
CN108004187A (en) A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines
CN105543126A (en) Lactobacillus plantarum JM113 and application thereof
Shi et al. Evaluation of safety and probiotic properties of a strain of Enterococcus faecium isolated from chicken bile
CN110577919A (en) heat-resistant bifidobacterium animalis subsp lactis separated from infant feces
CN106520599A (en) Lactobacillus reuteri and applications
CN107267415A (en) A kind of lactobacillus reuteri and its application for preparing vagina antibacterial medicines
CN106520598A (en) Lactobacillus rhamnosus and application
CN111040959A (en) Grass carp source lactic acid bacteria with specific pathogenic microorganism antagonistic capability and application thereof
CN106511976A (en) Composition for relieving gynecologic inflammation and improving immunity
CN117844692B (en) Lactobacillus taiwan and application thereof
CN112063566B (en) Enterococcus faecium and application thereof
CN107158041A (en) A kind of probiotic composition for being used to treat gynaecological imflammation
CN102337227B (en) Lactobacillus plantarum and purpose thereof
CN110938563B (en) Lactobacillus BJ-REBORN001 and application thereof in preparation of helicobacter pylori inhibiting fermentation broth
CN104673702A (en) Lactobacillus curvatus and pharmaceutical application thereof
CN113980838A (en) Bacillus subtilis capable of efficiently and directionally expressing bacteriocin M6 and application thereof
CN107260796A (en) Application of the thyme compound plant essential oil in preventing and treating chicken necrotizing enterocolitis
CN109536404B (en) Bacillus pumilus for feed and application thereof
CN111004734A (en) Lactobacillus rhamnosus capable of regulating and controlling relative abundance of acinetobacter in intestinal tract
CN117363511B (en) Webster-fused-type medicine capable of improving colpitis diseases and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170915

RJ01 Rejection of invention patent application after publication